HanchorBio Expands HCB101's Potential Through InxMed Combination Research
Event summary
- HanchorBio's subsidiary FBD Biologics signed an MOU with InxMed on July 8, 2026 to evaluate HCB101 in combination with InxMed's investigational assets IN10018/ifebemtinib and OMTX705.
- The partnership focuses on preclinical and translational research targeting difficult-to-treat solid tumors through macrophage-centered immune activation paired with drugs addressing tumor defenses.
- HCB101, a SIRPα-Fc fusion protein, is currently anchored in gastric cancer clinical development but is being explored for broader applications.
- InxMed's lead asset IN10018/ifebemtinib has advanced to Phase III trials and received FDA Fast Track designation.
The big picture
This collaboration aligns with HanchorBio's 'anchor-and-expand' strategy, aiming to establish clinical value in defined tumor settings like gastric cancer before extending into other biologically selected solid tumors. The partnership with InxMed, a specialist in cancer drug resistance and tumor microenvironment biology, reflects a broader industry trend of targeting tumor defenses to enhance treatment efficacy.
What we're watching
- Combination Therapy Potential
- How the translational data from this collaboration will influence HCB101's development path and potential as a combination backbone for solid tumors.
- Strategic Expansion
- Whether HanchorBio can successfully extend HCB101's value beyond its initial clinical anchors into broader oncology applications.
- Pipeline Reinforcement
- The pace at which this partnership could reinforce the value of HanchorBio's FBDB™ platform and its position in the competitive oncology landscape.
Related topics